Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Common Equity (2016 - 2025)

Cumberland Pharmaceuticals' Common Equity history spans 16 years, with the latest figure at $27.7 million for Q2 2025.

  • For Q2 2025, Common Equity rose 6.33% year-over-year to $27.7 million; the TTM value through Jun 2025 reached $27.7 million, up 6.33%, while the annual FY2024 figure was $22.9 million, N/A changed from the prior year.
  • Common Equity for Q2 2025 was $27.7 million at Cumberland Pharmaceuticals, down from $28.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $47.8 million in Q2 2021 and bottomed at $22.9 million in Q4 2024.
  • The 5-year median for Common Equity is $36.0 million (2023), against an average of $35.5 million.
  • The largest annual shift saw Common Equity crashed 31.37% in 2024 before it grew 6.33% in 2025.
  • A 5-year view of Common Equity shows it stood at $42.6 million in 2021, then decreased by 15.56% to $36.0 million in 2022, then dropped by 0.89% to $35.7 million in 2023, then crashed by 35.9% to $22.9 million in 2024, then increased by 21.11% to $27.7 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Common Equity are $27.7 million (Q2 2025), $28.3 million (Q1 2025), and $22.9 million (Q4 2024).